Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telemedicine vs In-Person Buprenorphine for Opioid Use Disorder
NCT05339256Phase 2Withdrawn
- Sponsor
- New York State Psychiatric Institute
- Start
- Jun 2026
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
01
Overview
A Phase 2 trial of v1003 in opioid use disorder (OUD), sponsored by New York State Psychiatric Institute. Planned start Jun 2026; status: withdrawn.
02
Drugs
v1003
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT05339256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05339256.